Nucala patent expiry date?

When does the Nucala (mepolizumab) patent expire?

I don’t have enough provided information to state a specific Nucala patent expiry date. Patent expiry depends on the exact patent(s) covering mepolizumab (including any secondary patents and exclusivity terms), and the date can vary by jurisdiction.

What determines the “patent expiry” date for Nucala?

For drugs like Nucala, the end of market exclusivity can be driven by multiple layers, including:
- The expiration of specific composition-of-matter or formulation patents
- Additional “secondary” patents (for example, specific indications, methods of use, or manufacturing)
- Regulatory exclusivity terms tied to approval and data protection (which may extend beyond the earliest patent expiration)

Because different patents can expire on different dates, it’s common to see multiple potential “expiry” timelines rather than one single date.

Where can I check the exact Nucala patent expiry timeline?

DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including multiple patents and related dates. You can use it to identify the latest relevant expiry date(s) for Nucala’s U.S. coverage: DrugPatentWatch: Nucala (mepolizumab)

If you tell me the country/region you care about (e.g., U.S., EU, UK) and whether you mean the earliest patent expiry or the last exclusivity date preventing biosimilar entry, I can help narrow down what “expiry” likely means for your use case.

Sources

1. DrugPatentWatch: Nucala (mepolizumab)